

Dr David Fisher

David is the foundation CEO of GI Therapies Pty Ltd. David is also a Venture Partner with Brandon Capital Partners having helped found the business in 2007. David had previously established, Brandon Capital Management, the Investment Manager for three life sciences Pooled Development Funds in 1999, including providing the initial seed funding for Nanosonics Limited (ASX:NAN).

Before this, David was foundation CEO of Peptech Limited. During this period Peptech went from a start-up to having R&D operations in Australia, the UK, the US and manufacturing operations in Denmark. Prior to Peptech, David spent ten years with Pharmacia AB (now part of Pfizer, Inc), including five years at their head office in Sweden.

David is also a director Global Kinetics Corporation P/L and Nanosonics Ltd. He is a past President of the Australian Biotechnology Association and past Chairman of the CSIRO's Division of Animal Production Industry Advisory Committee. He has a first class Honours degree in Rural Science, a PhD in Chemical Engineering from the University of Sydney and a Masters degree in Applied Finance. David is a Fellow of Finsia and a graduate of the Institute of Company Directors.